Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) PT at $175.00

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) have received an average rating of "Moderate Buy" from the fifteen ratings firms that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $175.00.

A number of equities analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, November 7th. Wells Fargo & Company dropped their price objective on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an "equal weight" rating for the company in a report on Thursday, August 1st. Royal Bank of Canada lifted their price target on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. upped their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an "overweight" rating in a research report on Monday, August 19th. Finally, Robert W. Baird decreased their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an "outperform" rating for the company in a research report on Thursday, August 1st.

Insiders Place Their Bets

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares of the company's stock, valued at approximately $1,573,707.30. This represents a 8.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,110 shares of company stock worth $720,160 over the last three months. Insiders own 4.20% of the company's stock.

Institutional Trading of Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of JAZZ. Versant Capital Management Inc lifted its holdings in shares of Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company's stock worth $29,000 after purchasing an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of Jazz Pharmaceuticals in the second quarter worth approximately $29,000. EverSource Wealth Advisors LLC grew its stake in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company's stock valued at $30,000 after buying an additional 97 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company's stock valued at $31,000 after acquiring an additional 116 shares in the last quarter. Finally, Gladius Capital Management LP bought a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $33,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Down 2.6 %

Shares of JAZZ stock traded down $3.38 during trading on Thursday, hitting $124.27. 840,820 shares of the company were exchanged, compared to its average volume of 678,116. The firm has a market capitalization of $7.51 billion, a price-to-earnings ratio of 17.58, a P/E/G ratio of 1.07 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The business's 50-day simple moving average is $111.61 and its 200 day simple moving average is $110.18. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $134.17.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.